Cardiosense announced today that it received FDA 510 (k) clearance for its CardioTag wearable sensor device.

Gender-affirming hormone therapy does more than reshape the body; it shifts the heart’s electrical rhythm, too, helping it ...

The new wearable technology can assess multiple cardiovascular metrics, including electrical impulses and blood flow, to alert patients and clinicians to worsening heart failure and other conditions.

Gender-affirming hormone therapies (GAHT) were associated with some cardiac repolarization alterations evident on ...

Contemporary atrial fibrillation (AF) screening relies on ECG and photoplethysmography in hospitals or on data derived from wearable devices, which are constrained by limited accessibility and high ...